News

Press Releases

Filter By

2017/07/24

STA Signs Supply Agreement with TESARO

SHANGHAI, July 24, 2017 --STA Pharmaceutical Co., Ltd. (STA) – a WuXi AppTec subsidiary and the leading open-access capability and technology platform for small molecule pharmaceutical development and manufacturing – announces it signed a supply agreement with the oncology-focused biopharmaceutical company, TESARO, Inc. (TESARO) for certain starting and intermediate materials for ZEJULA™ (niraparib).

Read more

2017/05/15

WuXi AppTec Completes Acquisition of HD Biosciences

SHANGHAI, May 15, 2017 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has completed its acquisition of HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).

Read more

2017/03/27

LabNetwork Integrates with Reaxys to Offer Seamless Experience from Chemistry Research to Purchase

SHANGHAI; BOSTON, Mass., 27 March, 2017 – LabNetwork, WuXi AppTec’s global chemistry ecommerce platform company, today announced a new collaboration with Elsevier, a world-leading provider of scientific, technical and medical information products and services.

Read more

2017/03/01

WuXi AppTec Lab Testing Division’s Bioanalytical Service Unit Passed FDA Inspection

Shanghai, Mar.1, 2017—WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform company, today announced that its Lab Testing Division(LTD)'s Bioanalytical facility in Shanghai once again passed US FDA's bioequivalence (BE) inspection with no 483 observations.

Read more

2017/01/20

WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

SHANGHAI, Jan. 20, 2017 -- WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform, today announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).

Read more